12 results
Causes of Diffuse and Localized Lymphadenopathy - Differential Diagnosis Algorithm
 • Reactive (Inflammatory / Infectious)
 •
Diagnosis Algorithm ... Lymphadenopathy #LAD ... #Differential # ... #Causes #Hematology ... #Oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... initiated after a LMWH lead-in ... bleeding risk during ... Anticoagulation #Management #Hematology ... #Oncology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... for the treatment ... for appropriate dosing ... Anticoagulation #Management #Hematology ... #Oncology
Recurrent / Breakthrough DVT During Anticoagulation

Subtherapeutic Anticoagulation
Hypercoagulable State 
 - Antithrombin deficiency 
 - Hypercoagulability ot
Breakthrough DVT During ... Recurrent #DVT #VTE ... anticoagulation #hematology ... #differential # ... algorithm
Causes of Diffuse Lymphadenopathy - Differential Diagnosis Algorithm
Reactive:
 - Systemic Inflammatory
     •
Diagnosis Algorithm ... Lymphadenopathy #LAD ... Diagnosis #Algorithm ... #Causes #Hematology ... #Oncology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... treatment #medications ... decisionaid #cardiology #hematology ... #warfarin #dosing
Causes of Localized Lymphadenopathy - Differential Diagnosis Algorithm
Cervical:
 - Anterior
     • Infection
Diagnosis Algorithm ... Lymphadenopathy #LAD ... #Differential # ... #Causes #Hematology ... #Oncology
Eosinophil Disorders Testing Algorithm
INDICATIONS FOR TESTING:
 • Peripheral blood eosinophilia/hypereosinophilia uncovered incidentally during medical evaluation or
Disorders Testing Algorithm ... uncovered incidentally during ... glucocorticoid treatment ... #Differential # ... diagnosis #hematology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Triggers: ATRA treatment ... initiation • Differential ... fluid overload, PCC ... diagnosis #management #hematology ... #oncology
Paraproteinemias

Entities That Can Feature A Monoclonal Protein/M Component:
• MM
• WM
• MGUS
• MGCS
• MGRS
• Splenic Marginal Zone
Autoantibodies: • WAIHA • CAD ... • PCH • Evans ... Paraproteinemias #Hematology ... #Monoclonal #Differential ... #Diagnosis #Oncology